Early Access — free while we kick the tires
EdgarHawk

Joseph Loscalzo

Director

Director

Latest: Director selling · May 2026

2 filings analyzed · 1 company · Latest 2026-05-06

Companies

Company Buys Sells Direction
IONIS PHARMACEUTICALS INC IONS 0 10 Net selling

Activity

May 2026
low
Sell
77,289 shares
$5,801,226
Significance 3/10

Director Joseph Loscalzo exercised options and sold all acquired shares on same day; proceeds exceed $5.8M despite unprofitable fundamentals.

Director Joseph Loscalzo executed a mechanical exercise-and-sell sequence on a single day: acquiring 77,289 shares across six option exercises at prices ranging from $38 to $64, then immediately selling all 77,289 shares at prices near $75, netting approximately $2M in proceeds. This is classic tax-efficient equity compensation vesting, not a bet on the company's direction. Loscalzo's sole prior Form 4 activity was a sale in October 2025, whose outcome is not yet measurable, so no timing pattern can be established from his previous trades at this stock. Ionis itself remains unprofitable on an annual basis despite strong revenue growth, and the stock is trading noticeably below its 52-week high—context that makes the exercise-and-sell pattern routine compensation management rather than a statement about conviction in the business. The net zero share change confirms no cumulative accumulation or reduction in his exposure occurred.

November 2025
medium
Sell
16,000 shares
$1,201,669
Significance 5/10

Director LOSCALZO JOSEPH sold 16,000 shares of IONS at $75.10 for $1,201,668.80; post-transaction holdings: 36,330 shares

LOSCALZO JOSEPH sold 16,000 shares at $75.10 on 2025-10-31, reducing his holdings from 52,330 to 36,330 shares (-30.6% of pre-transaction position). The sale occurred at near 52-week highs: the transaction price of $75.10 is -0.9% from the 52-week high of $74.30 and reflects strong recent momentum (the stock posted +6.5% over 30 days and +71.1% over 90 days). Context is important: Ionis Pharmaceuticals reported revenue of $156,700,000 and net income of -$128,600,000 in the latest quarter, with full-year results also unprofitable and annual revenue declining -10.5% year-over-year, yet the company carries an $11.9B market cap. A significant director equity reduction at elevated prices during a period of strong stock appreciation warrants investor attention to the company's underlying fundamentals and the director's forward outlook.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access